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been detected in CD4 memory cells. In contrast, nei-University Hospital Charite´
Schumannstr. 20/21 ther resting nor activated monocytes or B cells express
this cytokine (Wolk et al., 2002).D-10117 Berlin
Germany Like all other members of the IL-10 family, IL-22 exerts
its biological effects via members of the cytokine recep-
tor family class 2. The cell surface-standing IL-22 recep-
tor complex consists of the receptor chains IL-22R1Summary
and IL-10R2 (Dumoutier et al., 2000b; Xie et al., 2000;
Kotenko et al., 2001a). The latter also functions as anInterleukin 22 (IL-22) is mainly produced by activated
Th1 cells. The data presented here indicate that neither accessory receptor chain for the IL-10, IL-26, and the
IL-28/IL-29 receptor complex (Langer et al., 2004). Rapidresting nor activated immune cells express IL-22 re-
ceptor, and IL-22 did not have any effects on these STAT tyrosine phosphorylation upon IL-22 treatment
was observed in several tissue cell lines (Dumoutier etcells in vitro and in vivo. In contrast, cells of the skin
and the digestive and respiratory systems represent al., 2000a, 2000b; Xie et al., 2000; Aggarwal et al., 2001;
Lejeune et al., 2002). As demonstrated in the H4IIE ratputative targets of this cytokine. The expression of
IL-22 receptor in keratinocytes was upregulated by hepatoma cell line, recombinant mouse IL-22 also in-
duced phosphorylation of Jak1 and Tyk2. Moreover,Interferon-. In these cells, IL-22 activated STAT3 and
directly and transcriptionally increased the expression activation of the three major MAP kinase pathways and
serine phosphorylation of STAT3 was suggested to beof -Defensin 2 and -Defensin 3. High levels of IL-22
were associated with strongly upregulated-Defensin required for maximum IL-22-induced transactivation of
STAT-responsive promoter in these cells (Lejeune etexpression in skin from patients with T cell-mediated
dermatoses. Taken together, IL-22 does not serve the al., 2002).
In addition to the cell surface IL-22 receptor complex,communication between immune cells but is a T cell
mediator that directly promotes the innate, nonspe- there is a soluble, single-chain IL-22 receptor named IL-
22 binding protein (IL-22BP), IL-22RA2, or CRF2s short,cific immunity of tissues.
which also demonstrates the features of the extracellular
domain of the class 2 cytokine receptors. It has beenIntroduction
shown to antagonize IL-22 cellular binding and signaling
in vitro (Dumoutier et al., 2001; Kotenko et al., 2001b;IL-22, together with IL-10, IL-19, IL-20, IL-24, and IL-26,
belongs to the IL-10 family of cytokines. IL-22 was first Xu et al., 2001; Gruenberg et al., 2001).
Although different cell lines have been shown to ex-described in 2000 as a gene differentially expressed in
IL-9-treated BW5147 murine T lymphoma cells (Dumou- press functional cell surface-standing IL-22 receptor
tier et al., 2000a). The human counterpart was identified complex, little is known about the biological role of IL-
a few months later based on its similarity to mouse IL- 22. In the HepG2 human hepatoma cell line, IL-22 upreg-
22 and human IL-10 (Dumoutier et al., 2000b; Xie et al., ulated mRNA expression of acute phase reactants such
2000). Both human and mouse cDNA encode proteins as Serum amyloid A (SAA), 1-Antichymotrypsin, and
of 179 amino acids with amino acid positions character- Haptoglobin. Rapid induction of SAA-specific mRNA
istic of the IL-10 family. They are 22% and 25% identical was also observed in mice upon application of murine
to human and mouse IL-10, respectively, and 79% iden- IL-22 (Dumoutier et al., 2000b). Additionally, murine IL-
tical to each other. The human IL-22-encoding gene is 22 was shown to induce mRNA expression of Pancreati-
located on chromosome 12q15 near the Interferon- tis-associated protein-1 in pancreas acinar cells and in
(IFN-) and the IL-26 locus. It comprises six exons and pancreas in vivo, a protein of unknown function that has
shows an organization similar to the genes of the other been associated with acute pancreatitis (Aggarwal et
IL-10 family members (Dumoutier et al., 2000c). In mice al., 2001).
the IL-22 gene was mapped on chromosome 10 also In order to achieve a better insight into the biological
importance of IL-22, this study aimed at the character-
ization of its targets by systematic analyses of cellular*Correspondence: robert.sabat@charite.de
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IL-22 receptor expression and of the biological effects and in vivo. First, we assessed the production of soluble
of IL-22 on selected cell populations. mediators in peripheral blood mononuclear cell (PBMC)
cultures by ELISA. As shown in Figure 2A, neither induc-
Results tion of Tumor necrosis factor  (TNF-), IL-10, IFN-,
IL-6, nor SAA could be detected in a kinetic study until 72
Lack of IL-22 Receptor Expression in Immune Cells hr. In contrast, LPS induced production of the mentioned
The close protein family relation between IL-22 to IL- cytokines. Additionally, no influence of IL-22 was seen
10 allowed us to suppose that IL-22 could also have in PBMC cultures with respect to constitutive and LPS-
extensive effects on immune cells. However, we have induced IL-1 receptor antagonist (IL-1RA), IL-8, and
recently shown that freshly isolated human monocytes, TNF-, and anti-CD3-induced IFN- production (data
T cells, and NK cells do not express IL-22R1, which is not shown).
the specific subunit of the IL-22 receptor complex. In B Second, PBMCs cultured for 24 hr in the presence or
cells, IL-22R1 expression levels near the detection limit absence of cell-specific stimuli as described above were
of the measuring method were detected (Wolk et al., screened for possible IL-22-induced modifications of
2002). Simultaneously, clear expression of IL-10R2, the cell membrane protein expression by means of flow
second subunit of the IL-22 receptor that also functions cytometry. No influence was found on monocytes (CD16,
as an R2 chain of the IL-10, the IL-26, and the IL-28/IL-29 CD54, CD64, and HLA-DR expression), B cells (CD25,
receptor complexes, was found in resting monocytes, B, CD69, CD71, and CD86 expression), T cells (CD25, CD69,
T, and NK cells. As there are Interleukin receptors that CD95, CD45RA, and CD45RO expression), and NK cells
are only expressed upon cellular activation (e.g., IL- (CD54 and CD69 expression). Figures 2B and 2C show
2R), we now asked whether stimulated immune cells examples with respect to monocytes and NK cells.
would express IL-22R1. Negatively separated mono- Whereas IL-10 downregulated HLA-DR and upregulated
cytes and B, T, and NK cells from the blood of different CD16 expression, and IFN- upregulated HLA-DR and
healthy donors were cultured in the presence or absence downregulated CD16 expression, no effect of IL-22 on
of the typical cell-specific stimuli lipopolysaccharide these monocyte parameters could be detected. Simi-
(LPS) (monocytes) and fixed Staphylococcus aureus larly, whereas IL-12 upregulated NK cell expression of
(B cells), immobilized anti-CD3 monoclonal antibody CD54 and CD69 that could be prevented by the presence
(mAb) (T cells), and IL-2/IL-12 (NK cells), respectively, of transforming growth factor (TGF)-, no influence of
for 2, 6, and 18 hr. Expression of IL-22R1 and IL-10R2 IL-22 on constitutive and IL-12-induced CD54 and CD69
was quantitatively analyzed by real-time polymerase expression could be observed in these cells. In contrast
chain reaction on reverse transcribed mRNA (qPCR). As to PBMCs, primary human hepatocytes responded to
shown in Figure 1A, no IL-22R1 expression was induced IL-22 by elevated production of SAA, although to a lesser
upon stimulation of either of the different cell popula- extent than after IL-6 stimulation (Figure 2D).
tions. Interestingly, the expression of IL-10R2 was We further investigated whether IL-22 would modify
slightly downregulated at all time points in B, T, and NK serum levels of cytokines in mice. As shown in Figure
cells, and at the first two time points in monocytes. To 3A, no induction of TNF-, IL-10, IFN- or IL-6 was ob-
analyze whether additional costimulation or the pres- served in a kinetic study with BALB/c mice until 72 hr
ence of cytokines known to induce functional polariza- after IL-22 injection, whereas LPS injection had clear
tion would induce IL-22R1 expression in T cells, the inducing effect. Furthermore, IL-22 did not modify LPS-
latter were cultured on anti-CD3 mAb/anti-CD28 mAb- induced plasma levels of TNF-, IL-10, or Macrophage
coated vessels in culture milieus known to induce polar- inflammatory protein 2 (MIP-2) in BALB/c mice 1.5 hr
ization toward T1 cells, T2 cells, or regulatory T cells, postinjection either (Figure 3B and data not shown). In
or let without polarization for 6 and 18 hr like above,
contrast, IFN- and IL-10 were able to counteract LPS-
and additionally for 42 and 66 hr (Figure 1B). Again, no
induced IL-10 and TNF-, respectively. No impact of
expression of IL-22R1 was observed in either of these
IL-22 was also found on IFN- and IL-6 levels 8 hr postin-groups. IL-10R2 downregulation was even much more
jection (Figure 3C). In line with published mRNA datapronounced in case of costimulation but did not vary
(Dumoutier et al., 2000b), IL-22 induced production ofbetween different polarization groups. IL-22R1 expres-
SAA, although to a minor extent compared to LPS, andsion was not detected either in resting and LPS-acti-
also enhanced LPS-induced SAA levels 1.5 hr postinjec-vated macrophages (Mφ) and dendritic cells (DCs) de-
tion (Figures 3A and 3B). Taken together, the absencerived from primary human monocytes (Figure 1C). In
of IL-22R1 in the analyzed immune cell populations as-these cells, activation also led to downregulated expres-
sociated with the absence of IL-22-induced modificationsion of IL-10R2. In contrast to immune cells, primary
of a range of immunological parameters in vitro andhuman hepatocytes, one of the two cellular targets of
in vivo strongly suggests that these cells are not targetsIL-22 action known so far, show clear expression of both
of IL-22 action.IL-22R1 and IL-10R2. Interestingly, the expression levels
of IL-22R1 and IL-10R2 in these cells were not modu-
IL-22 Receptor Expression in Variouslated by IL-6-induced activation (Figure 1D). In summary,
Nonimmune Tissuesour data suggest that IL-22 acts neither on resting nor
We then investigated human tissues for the expressionactivated immune cells.
of the IL-22 receptor subunits. As demonstrated in Fig-
ure 4A, all analyzed tissues expressed the IL-10R2 chain.Lacking Regulation of Immune Cell Function by IL-22
In contrast, only a limited number of tissues expressedTo confirm the suggested insensitivity of immune cells
toward IL-22 we performed functional studies in vitro IL-22R1, among them skin, small intestine, liver, colon,
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Figure 1. Neither Resting Nor Stimulated Human Immune Cells Express IL-22R1
(A) Isolated blood mononuclear cell populations were stimulated or not (controls) with LPS (monocytes), fixed Staphylococcus aureus cells
(B cells), IL-2/IL-12 (NK cells), or anti-CD3 mAb coated on culture vessels (T cells) for 2, 6, and 18 hr.
(B) Isolated T cells were stimulated with anti-CD3 and anti-CD28 mAbs coated on culture vessels in the presence of IL-12/anti-IL-4 mAb
(polarization toward T1 cells), IL-4/anti-IFN- mAb (polarization toward T2 cells), IL-10/TGF-1,2 (polarization toward regulatory T cells, T reg)
or isotypic control mAbs (no polarization, T0), or cultured without stimulation in the presence of isotypic control mAbs (control) for 6, 18, 42,
and 66 hr.
(C) Primary monocyte-derived Mφ and DCs were stimulated or not (controls) with LPS for 6 hr.
(D) Primary human hepatocytes were stimulated or not (control) with IL-6 for 18 hr.
IL-22R1 and IL-10R2 gene expression was analyzed by qPCR. Expression data relative to that of HPRT from two independent experiments
are given as mean  range.
lung, kidney, and, most prominently, pancreas. In line in KCs from seven donors showed a pattern similar to
that observed in human skin samples with average ex-with the results obtained with blood immune cell sub-
populations, no IL-22R1 was detected in bone marrow, pression levels of IL-10R2 of 3.7 (1.14) times higher
than that of IL-22R1 (Figure 4C). To investigate whetherPBMCs, thymus, and spleen. A pattern similar to that
observed in tissues was found in corresponding cell these expression levels would be regulated by cyto-
kines, KCs were cultured in the presence or absence oflines (Figure 4B). Whereas C170 colon tumor cells, Hep
G2 hepatocyte carcinoma cells, A549 lung carcinoma IFN- or IL-4 for 2, 6, 18, and 42 hr. As demonstrated
in Figure 4D, IFN- exposure strongly induced a progres-cells, MDA-MB-231 breast adenocarcinoma cells, BxPC-3
pancreatic adenocarcinoma cells, A3 sub E placenta sive increase of IL-22R1 and IL-10R2 that reached, at 42
hr, more than 600% and 300% of controls, respectively.cell line, and HaCaT keratinocyte cells expressed both
IL-22R1 and IL-10R2, the Jurkat T-lymphoblast cell line Both effects were dose dependent as demonstrated for
42 hr (Figure 4E). IL-4 had marginally, if any, downregu-and the THP-1 monocytic cell line expressed IL-10R2,
but not IL-22R1. lating effect on the expression of IL-22R1 (Figure 4D).
IL-22-Induced STAT3 Activation in KCsIL-22 Receptor Expression in Keratinocytes
Because of the high IL-22 receptor expression levels in In the next part of our study we asked for the effects of
IL-22 on KCs. First, we investigated whether IL-22 wouldskin and HaCaT cell lines, our further studies focused
on the main cells of the skin epidermis, the keratinocytes activate Jak-STAT pathways in these cells. 20 min IL-
22 exposure induced tyrosine phosphorylation of STAT3,(KCs). mRNA expression analysis of both receptor chains
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Figure 2. IL-22 Does Not Act on Human Blood Immune Cells In Vitro
(A) PBMCs were cultured in the presence of IL-22, LPS, or without stimulation (control) for 1, 3, 6, 24, 48, and 72 hr. Cell culture supernatant
was analyzed for TNF-, IL-10, IFN-, IL-6, and SAA content by ELISA. Data from three independent experiments are given as mean  SEM.
(B) PBMCs were cultured in the presence of varying concentrations of IL-22, IFN-, or IL-10 for 24 hr. Monocyte expression of HLA-DR and
CD16 was analyzed by flow cytometry. Data from three independent experiments are given as percent of untreated control calculated based
on measured mean fluorescence intensities (mean  SEM).
(C) PBMCs were cultured in the presence of varying concentrations of IL-22, or IL-22 or TGF- each in the presence of 10 ng/mL IL-12. NK-
cell expression of CD69 and CD54 was analyzed by flow cytometry. Data (mean  SEM) from three independent experiments are given as
percent of untreated control calculated based on measured percentages of positive cells (CD69) or mean fluorescence intensities (CD54).
(D) Primary human hepatocytes were cultured with IL-22, IL-6 or without stimulation (control) for 48 hr. SAA concentration of culture supernatant
was determined by ELISA. Data from three independent experiments are given as mean  SEM.
but not STAT1 and STAT5, demonstrating that the ex- further supporting the insensitivity of these cells toward
IL-22 (Figure 4F).pressed IL-22 receptor was functional in KCs (Figure
4F). This STAT3 phosphorylation was less marked than
that observed after exposure to IFN-, which addition- IL-22-Induced Upregulation of -Defensin (hBD)2
and 3 Expression in KCsally induced tyrosine phosphorylation of STAT1 and
STAT5. In contrast to KCs, no induction of STAT tyrosine Upon screening of a variety of different cellular parame-
ters in IL-22-treated KCs (including proliferation, pro-phosphorylation was observed in IL-22-treated PBMCs,
Figure 3. IL-22 Does Not Act on Immune Cells In Vivo
(A) Male BALB/c mice were i.p. injected with PBS (control), murine IL-22, or LPS. Directly before (0 hr) and 1, 3, 6, 24, 48, and 72 hr after
injection blood plasma was collected and analyzed for murine TNF-, IL-10, IFN-, IL-6 (0-72 hr), and SAA (0-6 hr) levels by ELISA. Data are
given from three mice per time point as mean  SEM.
(B) Female BALB/c mice were i.p. injected either with PBS (control), murine IL-22, or LPS in the presence or absence of murine IL-22, IL-10,
or IFN-. 1.5 hr postinjection blood plasma was collected and analyzed for murine TNF-, IL-10, and SAA levels by ELISA. Data are given
from eleven mice per group.
(C) Female BALB/c mice were i.p. injected either with PBS (control), murine IL-22, or LPS in the presence or absence of murine IL-22. 8 hr
postinjection blood plasma was collected and analyzed for murine IFN- and IL-6 levels by ELISA. Data are given from eleven mice per group.
Significance of cytokine-induced alterations of constitutive and LPS-induced plasma levels (B and C) was investigated by use of Kolmogorov-
Smirnov test for two samples (*p  0.05, **p  0.01, ***p  0.001).
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duction of cytokines, expression of cell membrane pro- IL-1 is the only cytokine produced by KCs that is known
to induce KC hBD expression, we tested the influenceteins) we found an influence of this cytokine on the
expression of hBDs. These small, cationic peptides have of IL-1RA presence during KC IL-22 stimulation. As
shown in Figure 6A, IL-1RA up to 1 g/mL had no effectbeen known for a long time as broad-spectrum, antimi-
crobial agents produced by epithelial cell (Lehrer and on the IL-22-induced hBD expression, whereas IL-22BP,
already at 0.2 g/mL, prevented this IL-22 action. WeGanz, 2002; Zasloff, 2002). As demonstrated in Figure
5A, KCs constitutively expressed high levels of hBD1 also treated KCs with IL-22 in the presence of the tran-
scription inhibitor actinomycin D (Act D), the proteinand hBD3 and very low levels of hBD2 as deduced from
qPCR analysis. 42 hr exposure toward IL-22 increased synthesis inhibitor cycloheximide (CHX), the nonclassi-
cal secretion inhibitor methylamine (MA), or the respec-the expression of hBD2 and hBD3 but had minimal if
any influence on hBD1. This increase was specific as it tive solvent controls for 18 hr. As shown in Figure 6C,
Act D completely prevented the IL-22-induced hBD2was blocked by the presence of anti-IL-22 antibodies
(Figure 5A) and was dose dependent (Figure 5B). IL- and hBD3 expression. CHX and MA did not affect these
IL-22 effects, and a slight enhancement of hBD3 expres-22-induced expression of hBD2 was also detected in
primary hepatocytes. In contrast, no effect of IL-22 sion was actually observed in the presence of CHX (Fig-
ures 6D and E). These data indicate that the observedwas detected on hBD1, hBD2, and hBD3 expression in
monocytes, although hBD1 and hBD2 expression could IL-22 effects were generally independent of de novo
protein synthesis and alternative protein secretion andbe upregulated by IFN- and LPS in these cells, corre-
sponding to published data (Duits et al., 2002) (see Sup- were transcriptionally regulated.
We also asked whether IL-22 would upregulate theplemental Data available online at http://www.immunity.
com/cgi/content/full/21/2/241/DC1/). We also tested expression of further antimicrobial proteins. In fact, we
found a clear induction of psoriasin (Figure 6F) whosethe time dependency of hBD induction in KCs and com-
pared it to the effect of other cytokines known to modu- Escherichia coli-selective activity was recently de-
scribed (Gla¨ser et al., 2001, J. Invest. Dermatol., ab-late hBD levels in epithelial cells (Mathews et al., 1999;
Jia et al., 2001; Liu et al., 2003). Cells were cultured in stract).
the presence or absence of IL-22, IFN-, IL-4, or IL-1
for 2, 6, 18, and 42 hr. Whereas IL-22 did not clearly Association of Elevated IL-22 Expression
with Elevated hBD Expression in Inflamed Skinmodulate hBD1 expression at any of the time points, it
progressively upregulated the expression of hBD2 and The fact that IL-22 induced hBDs in skin cells led to
the question about the relevance of this finding. WehBD3, reaching at 42 hr, on average, more than 1400%
and 500% of control levels, respectively (Figure 5C). investigated IL-22 expression in biopsies of healthy as
well as of diseased skin by means of qPCR. As shown inRegarding hBD2, IL-22 was comparably potent as IFN-
but much less potent than IL-1. IL-4 had a downregulat- Figure 7A, no IL-22 expression was observed in healthy
skin. In contrast, high IL-22 levels were detected in skining effect. Regarding hBD3, IL-22 was less effective than
IFN- but comparably potent as IL-1 although its effect from patients suffering from inflammatory skin diseases
such as psoriasis or atopic dermatitis. This upregulationstarted earlier compared to that of IL-1. The effect of
IL-4 on hBD3 expression strongly fluctuated depending was even more pronounced than the disease-associ-
ated modulation of IFN-, IL-1, and IL-1 expressionon the donor of the cells.
We subsequently investigated the mechanism of IL- (Figure 7A). We hypothesized that the observed cytokine
expression pattern, particularly the high IL-22 levels,22-induced hBD expression in more detail. Since a previ-
ous study emphasized the requirement of cellular differ- would be associated with elevated hBD levels in these
patients. In fact, the expression of hBD2 and hBD3 wasentiation for KC hBD2 production induced by IL-1 (Liu
et al., 2002), we investigated the effect of differentiation- strongly upregulated in diseased skin from patients with
psoriasis and atopic dermatitis (Figure 7A). At this, hBD2promoting elevated calcium concentration on IL-22-
induced hBD expression. As shown in Figure 6B, in- levels were, on average, 20 times higher in psoriasis
than in atopic dermatitis. No modification of constitutivecreased calcium concentration induced a clear increase
of constitutive, IL-1- and IL-22-induced expression of hBD1 levels was observed in either of these skin dis-
eases. A correlation analysis of hBD versus the differenthBD1 and hBD2, but not hBD3. However, the fold induc-
tion of hBD2 expression by IL-22 did not change. cytokine expressions in biopsies from 25 persons
(healthy or suffering from psoriasis or atopic dermatitis)The observed IL-22 effect could be a direct one or
might be mediated by the action of a mediator. Since revealed high positive correlation of hBD2 and hBD3
Figure 4. Expression of Functional IL-22 Receptor Complex in Different Human Tissues, Cell Lines, and Primary Human KCs
(A and B) IL-22R1 and IL-10R2 gene expression was analyzed in tissues and cell lines by qPCR. Data from two independent analyses are
given as relative to HPRT expression (mean  range).
(C) IL-22R1 and IL-10R2 gene expression was analyzed in cultured KCs by qPCR. Data from seven individual donors are given as relative to
HPRT expression.
(D) KCs were cultured in the presence and absence (control) of IFN- and IL-4 for 2, 6, 18, and 42 hr. IL-22R1 and IL-10R2 gene expression
was analyzed by qPCR. Data from three independent experiments are given as percent of controls (mean  SEM).
(E) KCs were cultured in the presence of different concentrations of IFN- for 42 hr. IL-22R1 and IL-10R2 gene expression was analyzed by
qPCR. Data from two independent experiments are given as percent of control (0 ng/mL) (mean  range).
(F) KCs and PBMCs were stimulated with IL-22, IFN-, or without additives (control). After 20 min, levels of tyrosine-phosphorylated STAT1,
STAT3, and STAT5, and total STAT3 were assessed by Western blot analysis.
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Figure 5. IL-22 Upregulates the Expression of hBDs in Human Primary KCs
(A) KCs were stimulated with IL-22 or not (control) each in the presence or absence of either neutralizing anti-IL-22 antibodies or control goat
IgG for 42 hr. Expression of hBD1, hBD2, and hBD3 was analyzed by qPCR. Data from two independent experiments are given as relative to
HPRT expression (mean  range).
(B) KCs were stimulated with varying concentrations of IL-22 for 42 hr. Expression of hBDs was analyzed by qPCR. Data from three independent
experiments are given as percent of control (0 ng/mL) (mean  SEM).
(C) KCs were stimulated with IL-22, IFN-, IL-4, IL-1, or let without additives (control) for 2, 6, 18, and 42 hr. Expression of hBDs was analyzed
by qPCR. Data from three independent experiments are given as percent of controls (mean  SEM).
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expression with IL-22 expression (see Table in Figure unresponsiveness of immune cells toward IL-22, they
cannot definitely exclude that a certain immune cell sub-7A) that might support the relevance of IL-22 to hBD
population under certain conditions might be responsiveexpression in inflamed skin.
toward this cytokine.
In contrast to immune cells, expression of IL-22R1Cellular Sources of IL-22
was detected in a range of human tissues including skinSince elevated IL-22 expression in diseased skin was
and tissues of the digestive and the respiratory systemdetected at the mRNA level, it must result from local
as well as in their corresponding cell lines. This is in lineproducers. This led to the question about the cellular
with data previously published by Aggarwal et al. (2001)source of this cytokine. Inflammatory skin diseases are
and Parrish-Novak et al. (2002). Interestingly, in mostcharacterized by activated KCs as well as by infiltration
cases the IL-10R2 expression was much higher thanof activated immune cells. As known, activated T and
that of IL-22R1. Assuming the association of equalNK cells, but not monocytes and B cells, are able to
amounts of R1 and R2 chain in functional receptor com-produce IL-22 upon appropriate in vitro stimulation (Fig-
plexes, excessive IL-10R2 might be present here to me-ure 7B and Wolk et al., 2002). To investigate whether
diate effects of another ligand (IL-10, IL-26, IL-28, or IL-KCs are also able to express IL-22, primary KCs were
29). Apart from pancreas, human skin demonstrated thecultured in the presence or absence of IFN-, IL-4, or
highest IL-22R1 expression among all tested tissues.IL-1 for 2, 6, and 18 hr. The expression of IL-22 and
This expression pattern was reflected by that found inIL-8 was analyzed by qPCR. As shown in Figure 7B, no
human primary KCs and the HaCat cell line and couldIL-22 expression could be detected under any of the
be regulated. In fact, IFN--induced upregulation of bothtested conditions. As expected (Larsen et al., 1989),
receptor chains suggests an elevated sensitivity of KCsKCs expressed high levels of IL-8, which was rapidly
toward IL-22 under T1 conditions.upregulated in the presence of IL-1 (Figure 7B). These
The IL-22 receptor complex appeared to be functionaldata suggest that local IL-22 production in skin diseases
in KCs as IL-22 induced tyrosine phosphorylation ofshould be derived from infiltrating lymphocytes rather
STAT3, but not STAT1 and STAT5, in these cells. Inter-than resident KCs. This also matches data from a murine
estingly, STAT3 has been shown to be important formodel of inflammation. In fact, systemic application of
skin homeostasis as deduced from the phenotype ofLPS known to activate not only resident monocytes/
K5-Cre:STAT3flox/ transgenic mice (Sano et al., 1999).macrophages and dendritic cells (DCs) but also tissue
Regarding other tissue cells, IL-22 has been shown tocells in the different organs (including KCs) induced cu-
induce activation of all three STAT molecules in TK10taneous MIP-2, but not IL-22 mRNA (Figure 7C).
human renal carcinoma as demonstrated by gel shift
assay and Western blot analysis (Xie et al., 2000). InDiscussion
HepG2 human hepatoma cells, however, nuclear trans-
location of STAT3 and also STAT1, but not STAT5,The aim of this study was to expand the knowledge
was detected upon IL-22-stimulation (Dumoutier et al.,about the biological role of the recently discovered cyto-
2000b). Regarding the murine system, the group of
kine IL-22. Despite its relation to IL-10, which represents
Renauld demonstrated nuclear translocation of STAT3
one of the most important Interleukins (Moore et al.,
and, to a lesser extent, of STAT5, but not STAT1, in
2001), IL-22 does not appear to affect immune cells.
MES13 mesangium cells (Dumoutier et al., 2000a). In
This conclusion is based on the following observations. another study about downstream events of IL-22 recep-
First, neither resting nor stimulated human monocytes, tor engagement, the same group demonstrated in H4IIE
Mφ, DCs, B, T, and NK cells showed expression of IL- rat hepatoma cells tyrosine phosphorylation of STAT1,
22R1. In contrast, the second chain of the IL-22 receptor STAT3, and STAT5 (Lejeune et al., 2002). Whether the
complex, IL-10R2, was highly expressed and regulated differences in all these studies are due to cell specificity
in these cells. The “isolated” expression of IL-10R2 is not and/or species specificity needs to be clarified by fur-
surprising since this molecule functions as accessory ther analyses.
chain also for the receptor complexes for IL-10, IL-26, To elucidate the kind of action that IL-22 exerts on
and IL-28/IL-29 (Langer et al., 2004). A similar expression KCs, we screened these cells in preliminary studies for
pattern was observed in Jurkat and THP-1 cell lines as IL-22-induced modifications without any positive result.
well as in human bone marrow, PBMCs, thymus, and However, the observed IL-22 receptor expression in a
spleen. Second, no STAT tyrosine phosphorylation was range of physiologically outer body barriers (besides
induced by IL-22 in PBMCs. Third, no influence of IL- skin, also tissues of the gastrointestinal and respiratory
22 on any of the tested immune cell populations was system) prompted us to address the question whether
found in vitro with respect to the release of cytokines IL-22 could regulate immunoprotection at these barriers.
and SAA, the expression of a variety of surface proteins, In fact, a specific, time- and concentration-dependent
and the hBD mRNA expression. Fourth, the systemic induction of hBD2 and hBD3 expression was observed
application of murine IL-22 in mice did not modify basal in KCs in response to IL-22. hBDs are very small, highly
or LPS-induced plasma cytokine levels. Lacking IL-22 positively charged proteins that kill bacteria, fungi, and
sensitivity with respect to constitutive and LPS-induced viruses. They are distinguished from -Defensins on the
TNF- and IL-6 production by murine splenic adherent basis of their size, the three characteristic intramolecular
cells and induction of immunoglobulins in human splenic disulfide bonds, and their expression sites. hBDs are
and tonsillar B cells was already indicated in earlier mainly expressed in skin and mucosal epithelia, where
studies (Xie et al., 2000; Aggarwal et al., 2001; Lecart et they form a barrier against microbial infections (Lehrer
and Ganz, 2002; Zasloff, 2002). hBD1 was shown to beal., 2002). However, despite all these data demonstrating
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highly and stably expressed whereas hBD2 and hBD3 in atopic dermatitis. Significantly lower hBD2 expression
in atopic dermatitis compared to psoriasis was recentlyare induced by bacteria and proinflammatory cytokines
(Mathews et al., 1999; Liu et al., 2002, 2003; Jia et al., also demonstrated by Ong et al. (2002). This may be due
to the inhibitory effect of IL-4 that has been described to2001). Recent studies also proposed the contribution of
hBDs to other immune responses. hBD2 was shown to be upregulated in atopic dermatitis (Leung and Bieber,
2003). Accounting for the defect skin barrier in bothinduce activation and degranulation of mast cells and
chemoattracts immature DCs and CD4memory T cells diseases, the difference in hBD2 expression matches very
well investigations showing high frequency of cutaneousthrough interaction with the chemokine receptor CCR6
(Yang et al., 1999; Niyonsaba et al., 2001). The IL-22- infections in atopic dermatitis and a relative resistance
to cutaneous infection in psoriasis (Christophers andinduced hBD2 and hBD3 upregulation in KCs observed
in our study was dependent on cellular differentiation, Henseler, 1987).
Regarding all data together, a hypothesis about thewas transcriptionally regulated, and was independent
of protein de novo synthesis and alternative protein se- role of IL-22 may be advanced. Upon local, e.g., bacterial
skin infection, specifically activated memory Th cellscretion, indicating a direct effect of this cytokine. The
fold induction of hBD2 and nBD3 expression in KCs produce IL-22, which, via induction of hBDs, contributes
to the clearance of skin infection by killing invadingby IL-22 was comparable to that observed by other
hBD inducers. pathogens as well as by activating local mast cells. Si-
multaneously, the hBDs prevent the invasion of furtherThe analysis of the promoter region down to 1000
base pairs revealed putative STAT binding sites in the pathogens. This may be particularly important for the
prevention of a second invasion of a different pathogenhBD2 and the hBD3 gene (data not shown). These could
be involved in the regulation of these genes by IL-22 that no specific immune response has been established
for. This can be important because the first infectionand IFN-. Further studies are needed to clarify whether
these sites are active and whether STAT3 activation is provokes activation, maturation, and migration to the
lymph nodes of tissue-resident immature DCs (Roakeessential for the IL-22 effects demonstrated here. Inter-
estingly, we have found putative binding sites for NF- et al., 1995). This leads to the lack of immature DCs in
local skin and therefore the lack of the prerequisite for	B, AP-1, and NF-IL-6 in the hBD2 gene promoter but
no NF-	B sites in the hBD3 gene promoter that may establishing a specific immune response toward the
second pathogen. Without the T cell-dependent protec-explain the more slightly regulation of hBD3 compared
to hBD2 by IL-1 (data not shown). tion, these (second) pathogens would easily invade the
body. Additionally, IL-22, via induction of hBDs, che-IL-22-induced hBD expression might be relevant in
T cell-mediated inflammatory skin diseases. Indeed, moattracts immature DCs to the site of infection, thereby
reducing this “defenseless” phase. hBDs also chemoat-high levels of IL-22 expression were found in diseased
skin from patients suffering from psoriasis or atopic tract CD4 memory cells, the major source of IL-22,
suggesting a positive feedback mechanism. Upon sys-dermatitis that are probably derived from activated
temic inflammation, systemically present IL-22, via theT cells. Moreover, whereas the expression of hBD1 was
mentioned mechanisms, might provide protection in allnot changed in these patients compared to healthy con-
outer barriers. Our further, preliminary data suggest thattrols, the expression of hBD2 and hBD3 was highly in-
IL-22 particularly plays a unique role in chronic systemiccreased. Comparison of cutaneous expression of IL-22
inflammation. Taken together, IL-22, a cytokine pro-and other hBD inducers (IL-1, IL-1, IFN-, TNF-) in
duced mainly by activated Th1 but also by other acti-patients versus healthy controls and the fact that IL-1
vated T cells and by activated NK cells, has many targetsactivity is reduced in diseased skin (Hammerberg et al.,
among tissue cells and seems to directly increase the1992) might suggest a role of IL-22 in the upregulated
innate, nonspecific immunity against pathogens (induc-expression of hBD2 and hBD3. Unfortunately, we did
tion of acute phase protein and hBD expression) withoutnot succeed in establishing a detection method for IL-
(directly) affecting immune cells.22 protein to substantiate these suggestions. It is also
possible that additional mediators such as other mem-
Experimental Proceduresbers of the IL-10 family (e.g., IL-20) contribute to the
elevated skin hBD expression. Interestingly, whereas Cell Culture
expression of hBD3 was similar in both diseases, the Human total PBMCs, monocytes, NK, B, and T cells were isolated
from healthy donors and cultured as described previously (Wolk etexpression of hBD2 was much higher in psoriasis than
Figure 6. The IL-22-Induced Upregulation of hBD2 and hBD3 Expression in Human Primary KCs Is a Transcriptionally Regulated, Direct Effect
that Increases Upon Elevated Medium Calcium Concentration
(A) KCs were stimulated or not (control) with IL-22 in the presence of IL-1RA, IL-22BP, or medium for 18 hr. Expression of hBDs was analyzed
by qPCR. Data from three independent experiments are given as relative to HPRT expression (mean  SEM).
(B) KCs were stimulated with IL-22, IL-1, or let without cytokine (control) in the absence (low Ca2, 0.15 mM) or presence (high Ca2, 1.3
mM) of elevated calcium concentration for 18 and 42 hr. Expression of hBDs was analyzed by qPCR. Data from three independent experiments
are given as percent of 18 hr controls with low Ca2 (mean  SEM).
(C–E) KCs were stimulated or not (control) with IL-22 in the presence of Act D, CHX, MA, or the respective control solvent for 18 hr. Expression
of hBDs was analyzed by qPCR. Data of IL-22-stimulated samples from three independent experiments are given as percent of controls
(mean  SEM).
(F) KCs were stimulated or not (control) with IL-22 or IL-1 for 18 and 42 hr. Psoriasin expression was analyzed by qPCR. Data from three
independent experiments are given as relative to HPRT expression (mean  SEM).
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Figure 7. High Levels of IL-22 Seem to Derive From Infiltrating Immune Cells and Are Associated With Upregulated hBD Expression in Human
Psoriatic and Atopic Skin
(A) Cutaneous expression of IL-22, IFN-, IL-1, IL-1, and hBDs in patients with psoriasis, atopic dermatitis, and healthy probands was
analyzed by qPCR. (Bar chart) Data from five donors per group are given as relative to HPRT expression (mean  SEM). Significance of
alterations was investigated by use of Kolmogorov-Smirnov test for two samples (*p 
 0.05). (Table) Spearman’s rang correlation coefficients
for correlation between skin hBD and cytokine expression calculated from a total of 25 persons are indicated. Significance of correlation is
marked (*p 
 0.05, **p 
 0.01, ***p 
 0.001).
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al., 2002). For analyses of IL-22 receptor and IL-22 gene expression, lysing solution (Invitek, Berlin, Germany), were homogenized during
thawing by means of Ultraturrax tissue homogenizer (Jahnke andcells were stimulated or not (controls) with LPS (monocytes); fixed
Staphylococcus aureus cells (B cells); IL-2/IL-12 (NK cells); anti- Kunkel, Staufen, Germany). Murine samples were additionally
treated afterwards with 4 mg/mL proteinase K for 1 hr (ClontechCD3 mAb (total T cells) for 2, 6, and 18 hr; or, for costimulation and
functional polarization of T cells, cultured either in the presence of Laboratories). Isolation of total cellular RNA was done by use of
Invisorb RNA kit II (Invitek). mRNA was reverse transcribed andcontrol mAbs (controls) or stimulated with anti-CD3 and anti-CD28
mAbs in the presence of control mAbs (T0), IL-12/anti-IL-4 mAb analyzed by TaqMan PCR with the ABI Prism 7700 Sequence De-
tection System (Applied Biosystems, Weiterstadt, Germany) as de-(T1), IL-4/anti-IFN- mAb (T2), or IL-10/TGF-1,2 (T reg) for 6, 18,
42, and 66 hr, as described previously (Wolk et al., 2002). Mφ and scribed previously (Wolk et al., 2002). For detection of human
IL-22R1, IL-10R2, hBDs, IL-22, IL-4, and housekeeping gene hypo-DCs were generated by culturing isolated human monocytes for 5
days in the presence of M-CSF and for 7 days in the presence xanthine phosphoribosyl-transferase 1 (HPRT), as well as of murine
IL-22 and HPRT, we established detections systems with amplifi-of GM-CSF/IL-4. For analysis of STAT tyrosine phosphorylation in
PBMCs, isolated cells precultured for 24 hr, were incubated with cation efficiencies of 100% using exon-exon boundaries spanning
6-carboxy-fluorescein/6-carboxy-tetramethyl-rhodamine double-IL-22 or IFN- or let without additives for 15 min, and washed after-
wards for 5 min. To screen for possible IL-22-induced effects in labeled probes. All other detections systems used were purchased
from Applied Biosystems. Expressions were calculated relative toimmune cells, PBMCs were cultured in the presence or absence of
IL-22 or control mediators (IFN-, IL-10, TGF-, or LPS) for, if not the data for HPRT obtained with the every matching assay.
indicated otherwise, 3, 6, 24, or 48 hr. These studies were partially
(see Results section) performed in the presence of cell-specific
Micestimuli (LPS, S. aureus, IL-12  IL-2, anti-CD3 mAb) as described
To study the effect of IL-22 in vivo, three different experiments wereabove. For analysis of monocytic hBD expression, isolated mono-
conducted: First, 14-week-old male BALB/c mice were intraperito-cytes were cultured in the presence or absence of IL-22, IFN- or
neally (i.p.) injected with either phosphate-buffered saline (PBS),LPS for 18 and 42 hr. Primary human hepatocytes were obtained
1 g murine IL-22 (R&D Systems), or 100 g LPS from Escherichiafrom CellSystems (St. Katharinen, Germany), cultured on thin layer
coli 0111:B4 (Sigma-Aldrich). Before or after 1, 3, 6, 24, 48, and 72 hrBiocoat Matrigel (BD Biosciences, Heidelberg, Germany) in HCM
mice were sacrificed, and blood was drawn for the recovery ofmedium, and exposed or not to IL-6 or IL-22 for 18 and 48 hr. The
plasma. Second, 12-week-old female BALB/c were i.p. injected withcell lines C170, Hep G2, A549, MDA-MB-231, BxPC-3, A3 sub E,
either PBS, 1 g murine IL-22, or 300 g LPS (see above) in theJurkat, and THP-1 were purchased from the European Collection
presence and absence of murine IL-22, IL-10, or IFN- (each 1 g;of Cell Cultures (Salisbury, UK). HaCaT cells kindly provided by N.E.
R&D Systems). After 1.5 hr mice were sacrificed, and blood wasFusenig (Deutsches Krebsforschungszentrum, Heidelberg, Ger-
drawn for the recovery of plasma. Third, 12-week-old female BALB/cmany). Primary human KCs were obtained from CellSystems, cul-
were i.p. injected with either PBS, 1 g murine IL-22, or 300 g LPStured in KGM medium, and exposed to IL-22, IFN-, IL-4, IL-1,
(see above) in the presence and absence of 1 g murine IL-22. Afteror medium (controls) for the indicated times and in case of STAT
8 hr mice were sacrificed, and blood was drawn for the recovery ofphosphorylation assays, for 20 min. These studies were partially
plasma. Age and sex had influence on the induced serum SAA andperformed in the presence of polyclonal anti-IL-22 antibodies or
IFN- levels in these mice. For IL-22 gene expression analysis, 14-goat IgG, IL-1RA (0.25, 0.5, 1 g/mL), IL-22BP (0.2 g/mL), Act D
week-old male BALB/c were i.p. injected with 100 g LPS (see(0.25 g/mL; Sigma-Aldrich, Deisenhofen, Germany), CHX (1 g/
above). Before and after 1, 3, 6, 24, 48, and 72 hr mice were sacri-mL; Sigma-Aldrich), MA (1mM; Sigma-Aldrich), ethanol (solvent con-
ficed, and skin samples were taken. These studies have been ap-trol for Act D and MA; 0.02%), DMSO (solvent control for CHX;
proved by the regional authorities for provisions on labor, health,0.003%), or, as previously described by Liu et al. (2002), in the
and technical safety, Berlin.presence of elevated calcium concentration (1.3 mM). All cytokines
and antibodies mentioned above, as well as IL-1RA and IL-22BP,
were purchased from R&D Systems (Wiesbaden-Nordenstadt, Ger-
ELISA
many) with the exception of anti-CD3 mAb, which was purchased
Human SAA and murine SAA and TNF- were quantified by ELISA
from Cilag (Orthoclone; Sulzbach, Germany). If not indicated other-
from Biosource (Camarillo, CA). Human IFN- and mouse IL-10,
wise, all cytokines and soluble mAbs were applied at 10 ng/mL and
IFN-, IL-6, and MIP-2 were quantified by using ELISAs from R&D
5 g/mL, respectively. LPS derived from Escherichia coli 0127:B8
Systems. Detection of human TNF-, IL-10, and IL-6 was realized
was purchased from Sigma-Aldrich and used at 100 ng/mL.
by Immulite system (DPC Biermann, Bad Nauheim, Germany).
Flow Cytometry
Assessment of composition of isolated cell populations and confir- Western Blot Analysis
mation of cellular activation were performed by flow cytometry as Cell lysing, protein electrophoresis, and Western blotting was per-
previously described (Wolk et al., 2002). For functional assays the formed as described previously (Wolk et al., 2003). Blotted samples
following fluorescence-labeled mAb clones were used: UCHT1 were incubated with polyclonal antibodies against phospho-STAT1
(CD3), RM052 (CD14), 3G8 (CD16), N901 (CD56), NC1 (CD57), 22 (Tyr 701), phospho-STAT3 (Tyr 705), phospho-STAT5 (Tyr 694), or
(CD64), BMA031 (TCR), IMMU510 (TCR), 679.1 Mc7 (IgG1) (all total STAT3 (all from Cell Signaling Technology, Beverly, MA) and
from Coulter Immunotech, Hamburg, Germany), SK1 (CD3), SK3 peroxydase-conjugated AffiniPure goat anti-rabbit IgG (H and L)
(CD4), S-HCL-3 (CD11c), 4G7 (CD19), 2A3 (CD25), HI100 (CD45RA), (Dianova, Hamburg, Germany), followed by ECL detection (Amer-
UCHL1 (CD45RO), L78 (CD69), Lo1.1 (CD71), 2331 (CD86), DX2 sham Pharmacia Biotech, Freiburg, Germany).
(CD95), L243 (HLA-DR), 338 15X (IgG1/	), X40 (IgG1/	), X39
(IgG2a/	), G155-178 (IgG2a/	), 27-25 (IgG2b/	) (all from BD Biosci-
ences). Patients’ Skin Biopsies
Punch biopsies were obtained from diseased skin from adult pa-
tients either with chronic plaque psoriasis, with atopic dermatitis,Gene Expression Analysis
Total RNA from human tissues was obtained from Clontech Labora- or from healthy skin. These biopsies were approved by the Clinical
Institutional Review Board of the medical faculty Charite´ Berlin.tories (Heidelberg, Germany). Skin biopsies, snap frozen in Invisorb
(B) Blood T and NK cells and KCs were stimulated or not with either anti-CD3 mAb (T cells), IL-2/IL-12 (NK cells), or IFN-, IL-4, or IL-1 (KCs)
for 2, 6, and 18 hr. Expression of IL-22 (T and NK cells, KCs) and IL-8 (KCs) was analyzed by qPCR. Data from three independent experiments
are given as relative to HPRT expression (mean  SEM).
(C) BALB/c mice were i.p. injected with LPS. Expression of murine IL-22 and MIP-2 was analyzed by qPCR in skin samples taken before (0
hr) and 1, 3, 6, 24, 48, and 72 hr after injection. Data referring to three mice per time point are given as relative to HPRT expression (mean SEM).
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